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Abstract
Glycomacropeptide (GMP) is a milk-derived bioactive peptide that comprises 
15–20% of proteins present in whey, being the third most abundant. It is released 
from κ-casein by enzymatic digestion, either physiologically or in industry during 
cheese making process. GMP has many biological activities that are of particular 
interest for the manufacture of novel functional foods. Specifically, health promot-
ing activities of this whey peptide are related to: antimicrobial, anticariogenic, 
gastric acid inhibitory, cholecystokinin releasing, prebiotic, and immune modula-
tory. GMP is also a peptide with promising use in food industry, due to its nutri-
tional value and its emulsifying, foaming, and gelling properties. Besides, GMP 
has received much attention due to its use as an indicator of milk adulteration with 
cheese whey. This chapter summarizes the current knowledge about biological 
activities of GMP, going in-depth in immune regulatory properties, exposes the 
potential uses of GMP in industry, and finally reviews different methods used to 
detect GMP as adulteration index with cheese whey.
Keywords: glycomacropeptide, bioactive peptide, health promoting activities,  
whey component, milk adulteration
1. Introduction
As already mentioned in other chapters, milk whey is a liquid by-product 
generated after obtaining cottage cheese or curd (proteins coagulated by acid and 
heat), also known as cheese whey, that for many years has been considered a waste 
product, and sent to bodies of water, soil, and sewage systems. However, currently 
it is used due to its multiple nutritional and functional properties [1].
In Mexico, the production of whey in 2016 was estimated at 1,010,000 tons, 47% of 
which was discharged to soil, drains, and bodies of water. Despite the fact that multiple 
uses have been found to cheese whey, this has become a serious environmental problem 
[2]. This by-product is composed of water, lactose, proteins, peptides, fat, and mineral 
salts [3]. One of the peptides of interest is glycomacropeptide (GMP), which is obtained 
after the coagulation of milk κ-casein during cheese production and represents 15–20% 
(w/w) of the total proteins contained in milk whey [4].
GMP is the C-terminal fragment released by the proteolytic action of the 
endopeptidase chymosin (renin) on κ-casein during the initial stages of cheese 
making, or by the action of pepsin during the gastric digestion. κ-casein is 
hydrolyzed at phenylalanine105-methionine106 bond, forming two very different 
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Figure 1. 
Primary structure of bovine GMP variant A and B, where ● indicates its three phosphorylation sites and ▲ the 
most important glycosylation sites. Modified from Thomä-Worringer et al. [6].
polypeptides. One is called para-κ-casein (residues 1–105), and it is slightly 
cationic at pH 6.6, hydrophobic and poorly soluble, which remains in cheese curd; 
and the other is GMP (residues 106–169), that is strongly polar so diffuses into 
the aqueous phase, being eliminated during the draining with the cheese whey (as 
reviewed in [5]).
2. Chemical properties and molecular structure of GMP
GMP has 64 amino acid residues, with an isoelectric point (pI) between 4  
and 5. Fifty percent of GMP is deglycosylated and is known as caseinomacropep-
tide (CMP) [5]. However, milk GMP can present different types of carbohydrates, 
such as: sialic acid, galactosyl, and N-acetylgalactosamine, which generate dif-
ferent glycosylated forms of the molecule. GMP is rich in amino acids such as 
proline, glutamine, serine, and threonine, but deficient in tryptophan, tyrosine, 
phenylalanine, and cysteine. The absence of aromatic amino acids in its primary 
structure causes that GMP does not present absorption at the wavelength of 
280 nm. However, GMP can be detected at wavelengths between 205 and 226 nm 
and absorption differences between 210 and 280 nm are used for the character-
ization of GMP (as reviewed in [5]). The composition of GMP can be variable 
and depends on the source of serum and the fractionation technology used in its 
isolation [3] (Figure 1).
As reviewed by Neelima [7], the three-dimensional structure of GMP can-
not be evaluated due to its crystallization which is not possible, so it can only be 
seen from a purely theoretical approach. GMP is a peptide that does not possess 
defined secondary and tertiary structure. However, three-dimensional structure 
of GMP has been predicted by means of protein modeling and shows that a large 
part of the peptide has a strong negative charge, whereas there are three small 
domains with a positive charge at the N-terminal end. At pH 7.0, its mean value 
of the hydropathy is −0.322, and GMP is more hydrophilic than hydrophobic. 
The hydropathy value decreases when glycosylation of GMP increases, due to the 
greater amount of sialic acid residues.
3. Biological activities of GMP
The use of GMP is growing, since it is a bioactive peptide with unique nutritional 
and nutraceutical properties. Many biological activities of GMP have been reported, 
highlighting antimicrobial, anticariogenic, gastric acid inhibitory, cholecystokinin 
(CCK) releasing, prebiotic, and immune modulatory. Of particular interest is 
GMP’s capacity to modulate the immune response, due to its potential use in treat-
ment or prevention of different immunopathologies.
3Glycomacropeptide: Biological Activities and Uses
DOI: http://dx.doi.org/10.5772/intechopen.82144
One of the first antimicrobial effects observed in GMP was due to its ability 
to bind cholera toxin and Escherichia coli enterotoxins. Chinese hamster ovary 
(CHO)-K1 cells undergo morphological changes in presence of cholera toxin and 
GMP at 20, 100, and 1000 μg/mL was able to suppress this morphological change 
by more than 70%. Treatment of GMP with proteinases lowered this activity, 
but removal of sialic acid abolished it [8]. Curiously, as GMP doses increased the 
inhibitory effect decreased. Authors demonstrated that sialic acid is mediating this 
inhibitory activity, so it could be inferred that GMP at high doses has less sialic acid 
available probably as consequence of its aggregation into polymers. Likewise, GMP 
has showed inhibitory activity on CHO-K1 cells morphological change induced by 
E. coli thermolabile enterotoxins [9]. Later, the binding ability of GMP to intestinal 
pathogenic bacteria was evidenced, mainly to entherohemorragic E. coli (EHEC 
O157). This activity decreased when the peptide was desialylated and peroxidated, 
showing that sialic acid is essential to GMP attachment. Besides, GMP prevented in 
a dose-dependent manner the adhesion of EHEC O157 to Caco-2 cells and when it 
was conjugated with xylooligosaccharide or carboxymethyldextran, the release of 
IL-8 by Caco-2 was also suppressed [10]. The same inhibitory effect on pathogenic 
bacteria adhesion to Caco-2 cells was corroborated with 3[H] thymidine-labeled 
enterophatogenic E. coli (EPEC) Salmonella typhimurium or Shigella flexneri [11]. 
Besides, it has been reported that GMP generates dose-dependent inhibition of 
enterotoxigenic E. coli (ETEC) K88 adhesion to ileal mucosa in vitro [12]. Finally, a 
recent report showed that GMP also prevents the attachment of several strains of 
EHEC and EPEC to Caco-2 and HT-29 mammalian cells [13]. In this study, it was 
demonstrated that GMP, beyond inhibiting bacterial adhesion, is able to maintain 
the structural integrity of tight junctions on Caco-2 monolayers, thus delaying the 
paracellular translocations of EPEC. However, it is important to clarify that authors 
did not measure the expression level of proteins associated with these junctions.
There are several in vivo assays that show a probable protective effect of GMP against 
pathogenic bacteria. GMP has been reported to neutralize in 80% the rate of incidence 
of diarrhea induced by cholera enterotoxins LT-1 in mice, and abolished that induced 
by LT-2 [9]. On the other hand, the addition of GMP into diets of piglets diminished 
the bacterial count in mucosal scrapping and abated the attachment of ETEC K88 to 
the intestine, mainly on the ileal mucosa where the receptor for E. coli is located [12]. 
Moreover, a diet supplemented with 1% GMP protected weaning piglets from damage 
caused by E. coli infection, and prevented the reduction of growth, morphological dam-
age, and the increase in intestinal permeability associated to infection [14].
In association with this antimicrobial effect, an anticariogenic activity to 
GMP has been demonstrated. Firstly, in vitro assays using different products that 
contain GMP as an active principle showed that it could inhibit the adhesion of 
bacteria inducing dental plaque and carious in oral cavity to surface plastic, such 
as Streptococcus mutans, S. sanguis, and Actinomyces viscosus [15]. Later assays 
corroborated these results, as the incorporation of GMP with or without caseino-
phosphopeptide to salivary films modified the adhesion capacity of S. sobrinus and 
S. mutans to bovine enamel discs [16]. This antimicrobial effect was linked to a 
remineralization activity of GMP, as demonstrated later through an experimental 
protocol in human that showed that GMP alone or combined with xylitol promotes 
more remineralization than commercial fluoride toothpaste [17]. The anticariogenic 
and remineralization activity of GMP have been claimed in several patents [15, 17].
Several studies have related GMP with the inhibition of gastric secretion. First 
ones were mostly developed using dogs by a group of Russian researchers. The first 
evidence that GMP inhibits gastric secretion was showed by Shlygin and co-workers 
[18] using gastrin to evoke it. Subsequent works demonstrated similar effect using 
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different gastric secretion stimulants [19]. Some years later, it was proposed that 
this inhibitory effect was caused by a GMP fragment rather than the whole molecule 
[20, 21]. Later, injecting dogs with a protein fraction obtained from the gastric 
content of unweaned rats, it was observed an inhibition in dog gastric secretion 
to a food stimulus [22]. This inhibitory action was similar to that induced by GMP 
in dogs. GMP was also demonstrated to inhibit gastric motility after its intrave-
nous injection in dogs [23]. All these experiments point out that at physiological 
conditions GMP may be playing a crucial role in the preservation of active milk 
proteins in newborn animal during natural breast feeding. In addition to dogs, other 
experimental models such as rats, pigs, and calves and also isolated organs were 
used to demonstrate that GMP induces gastric secretion inhibition in association 
with a decrease in blood of some regulatory digestive hormones, as gastrin and CCK 
(as reviewed in [24]). However, variations in used gastric stimuli, GMP dose, and 
origin, via of administration and experimental approach may be the cause of the 
differences in the reported intensity to this GMP activity.
Related with the effect of this bioactive peptide on digestive hormones, GMP has 
also been associated with appetite control. Several in situ studies with Wistar rats 
have suggested that glycosylated forms of GMP A variant could regulate food intake 
through CCK secretion, a hormone involved in satiety, as GMP stimulate its release 
[25, 26]. Nevertheless, in studies in human, GMP had no effect in the regulation of 
food intake over a short-term period [27], neither in the loss of body weight after 
12 months of sustained consumption [28]. Likewise, GMP with different degree of 
glycosylation does not modify the concentration of CCK in human plasma [29]. As 
other authors have pointed out [27], these inconsistencies related to GMP’s effect on 
CCK release are probably due to dose changes in both animal models and human trials.
For many years, the prebiotic properties of GMP have been discussed. The first 
evidence that GMP might possess prebiotic activity arose with the bifidobacterial 
growth promoting effect of human’s colostrums and milk by in vitro assays [30]. 
In an attempt to discern the component of the milk responsible for this activity, 
an important role of N-acetyl-glucosamine (GlcNAc) and oligosaccharides with 
GlcNAc [31] was pointed out. Subsequent investigations were quite contradictory, 
until the prebiotic activity of GMP was demonstrated for the first time in 1984 
[32]. This work showed that human GMP is a promoter of bifidobacterial growth, 
although the effect was lost when it was hydrolyzed, as well as when bovine GMP 
was used, showing the importance of the GMP peptide chain to function as a pre-
biotic. Eight years later, it was reasserted that peptide fraction was decisive for the 
prebiotic effects on bifidus [33]; while other researchers leaned by sialic acid as the 
inductor of the effect [34]. Following this line, the supplementation of milk with 
2% GMP increased the in vitro growth of Bifidobacterium lactis [35]. Besides, the 
addition of 2 mg/mL of cow GMP to the growth medium, promoted the growth of 
Lactobacillus rhamnosus and Bifidobacterium thermophilum, and apparently glycosyl-
ation was not an essential factor to carry out this function [36]. On the other hand, 
using an artificial colon model to simulate colonic fermentation, GMP was shown 
to modulate the gut microbiota of elderly subjects by promoting the growth of 
several health-relevant taxa, like Coprococcus and Dorea, both related to resistance to 
pathobiont colonization [37]. Finally, a recent in vitro research has shown that GMP 
promotes the growth of Bifidobacterium longum ssp. infantis in a dose-dependent 
manner and modulates its genes expression. Again, they found that the effect was 
lost with periodate GMP, suggesting that its activity is due to the oligosaccharides 
present in the molecule [38].
In the last years, several research groups have demonstrated that oral treatment 
with GMP modifies in vivo the microbiota in gut using different experimental 
approaches. First works were developed in mice, and showed that after 15 days of 
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GMP treatment, there was a significant increase in Lactobacillus and Bifidobacteria 
in fecal samples, at the same time the number of Enterobacteriaceae and coliforms 
decreased [39]. Feeding mice for 8 weeks with a GMP-enriched diet reduced 
Desulfovibrio bacteria in normal and phenylketonuric mice; a bacteria that is 
associated with the pathogenesis of inflammatory bowel disease (IBD). Likewise, 
normal mice increased Firmicutes and phenylketonuric ones Bacteroidetes; 
specifically, the genus Allobaculum (associated with body weight loss [40]) and 
Bacteroidales, respectively [41]. In this case, the prebiotic property of GMP was 
associated with an increase in short chain fatty acid production, mainly acetate and 
propionate, that may has an important role in the regulation of immune response. 
So, although the prebiotic activity of GMP has been demonstrated, more research 
is needed to clarify whether the peptidic or carbohydrate fraction or both are 
involved in this bioactivity.
3.1 The immunomodulatory properties of GMP
GMP has been shown to modulate the immune response in a number of differ-
ent ways. First, we summarize literature reports about regulatory activity of GMP 
on immune cells demonstrated by in vitro assays, and later, we will focus on those 
studies in which the regulatory effect of GMP on immune response was analyzed in 
animal models.
In relation to the immunomodulatory effects of GMP on immune cells, different in 
vitro approaches have corroborated the inhibitory action of GMP on splenocyte prolif-
erative response to mitogens, and have shown that both sialic acid residues and poly-
peptide portions of GMP are essential in this inhibitory effect. In 1992, it was showed 
that the GMP fraction obtained from κ-casein inhibited proliferation of mouse spleno-
cytes induced by Salmonella typhimurium lipopolysaccharide (LPS) [42]. Furthermore, 
GMP displayed an inhibitory activity on the proliferative response induced by con-
canavalin A (Con A) and phytohemagglutinin (PHA) [42, 43]. Initially, it was found 
that sialic acid was the key in this inhibitory activity, as it was lost after digestion with 
neuraminidase [44]. However, the inhibitory effect of GMP was increased after diges-
tion with trypsin and pronase, which suggests that the peptidic chain is also involved in 
this immunomodulatory activity. In this regard, the same working group showed that 
the inhibitory effect on PHA-induced proliferative response is higher when the number 
of sialic acid residues is increased and that on LPS-induced proliferation is highest 
with a GMP fraction containing two sialic acid residues [45]. Both inhibitory effects 
decreased significantly after neuraminidase digestion. They also suggested that phos-
phate group at serine-149 plays a role in GMP binding to the mitogen receptor, as they 
observed a reduced inhibitory activity after GMP chymotrypsin digestion. Regarding 
to the associated mechanism to GMP inhibitory effect on splenocyte proliferation, it 
was showed that GMP stimulates the synthesis of a soluble inhibitory component, an 
interleukin (IL-1) receptor antagonist or IL-1ra [46, 47]. Moreover, GMP was able to 
bind to mouse CD4+ helper T cells and to suppress the expression of the IL-2 receptor 
on the cell membrane, inhibiting the PHA-induced proliferation of mouse splenocytes 
[48]. Subsequently, the inhibitory action of GMP on LPS-induced cellular proliferation 
was confirmed in mouse splenocytes, although they did not report any effect on PHA- 
or Con A-stimulated cells [49]. But later, controversy about the effect of GMP on the in 
vitro proliferation of spleen cells was generated, as it was reported that GMP increases 
the proliferation response of lymphocytes stimulated by Con A [50]. In this study, 
an increase in Foxp-3 and IL-10 expression was also demonstrated. Besides, authors 
showed an inhibition on secretion of IFN-γ and TNF-α and on STAT4 activation when 
cells were stimulated by Con A in presence of GMP. The same team studied the action 
of GMP on monocyte cell line THP-1 and they found that GMP increases the secretion 
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of TNF, IL-1β, and IL-8 by THP-1 cells, and this effect is mediated via MAP kinase and 
NF-kB pathways [51].
On the other hand, GMP is also able to downregulate dendritic cell response to 
LPS by inducing a slight but significant decrease in the production of IL-6, IL-1β, and 
TNF-α, but without changing the production of IL-12 and IL-10 [49]. Strikingly, the 
regulatory effect of GMP on neutrophils is the opposite, as it improves proliferation 
and phagocytic activity of the human macrophage like cells U937 [52]. However, 
the observation that both polypeptide and carbohydrate portions are essential for 
GMP biological effects is reinforced in this study, as peptides of pepsin-digested 
GMP and sialic acid-rich GMP fractions significantly enhanced cell proliferation and 
phagocytic activities stimulated by non-digested or asialo-GMP on U937 cell. Also, 
an upregulatory effect of GMP on production of IgA by LPS-stimulated splenocytes 
has been reported, being correlated with an increase in the population of IgA positive 
cells [53].
There are several studies that analyze the immunomodulatory activity of GMP 
on immune response when it is orally administered to experimental animals. In the 
context of splenocytes response to mitogens, two in vivo studies were carried out to 
analyze the possible immunomodulatory activity of GMP. First one was developed 
in 1998 and demonstrated that mice fed with a GMP-supplemented diet show an 
enhanced proliferative response of spleen cells to Con A, without generating signifi-
cant changes in the response to LPS or PHA [54]. Later in 2012, it was showed that 
oral intake of GMP by rats reduces the proliferative response of splenocytes induced 
by Con A [55]. In both in vivo studies, animals were antigen-immunized because 
antibody response was also measured. All together in vitro plus in vivo  studies, point 
out the inhibitory effect of GMP on splenocyte proliferation to mitogens. The oppo-
site response reported by one in vitro [50] and in vivo [54] assay was quite possibly 
due to concentration-dependent effects or assay-used conditions.
The effect of orally administered GMP on humoral immunity has also been 
studied. Mice fed with GMP have shown suppressed levels of specific IgG to dietary 
and injected antigens, with no change in IgM, IgA, and IgE antibody response 
[54]. In this regard, a recent study showed that oral administration of GMP to mice 
resulted in a greater number of IgA positive plasma cells in the intestinal lamina 
propria [56]. All these results [54, 56] plus in vitro ones [53] about Igs production fit 
together, suggesting an immuno-suppressing activity of GMP on systemic humoral 
response, but an immuno-stimulating activity on humoral mucosal immunity.
Martínez-Augustin and co-workers [57, 58] have studied the immunomodula-
tory action of GMP in experimental models of intestinal inflammation. They have 
demonstrated that GMP administered orally to rats exerts an anti-inflammatory 
effect in ileitis and colitis induced with trinitrobenzenesulfonic acid (TNBS); said 
anti-inflammatory effect shows a degree of efficacy similar to that of sulfasala-
zine, a drug widely used in the treatment of inflammatory bowel disease. GMP 
was shown to protect rats from TNBS-induced colonic and ileal inflammatory 
damage, by reducing the damage score and the extent of necrosis, and also by 
diminishing the increased alkaline phosphatase colonic activity and inducible 
oxide nitric synthase expression. IL-1β and IL-1ra messenger RNA levels were 
significantly decreased in colon as a consequence of GMP administration; and 
myeloperoxidase activity and levels of IL-1β and IL-17 were decreased in ileum. 
Initially, the authors assumed that the action mechanism of GMP was not related 
to anti-oxidative activity or to regulatory cell induction, as glutathione or TGF-β 
levels in colon and Foxp-3 in ileum were not affected [57, 58]. However, when GMP 
was orally administered to rats, an increase on Foxp3 expression in spleen cells was 
observed, although secretion of cytokines by ex vivo Con A-stimulated splenocytes 
did not change [50]. Putting together these results with the regulatory activity of 
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GMP on monocytes (THP-1) and splenocytes cytokine response obtained by the 
same working group and previously mentioned in this review [50, 51], authors 
concluded that the intestinal anti-inflammatory action of GMP is likely to be 
mediated by the direct modulation of monocyte or splenocyte activity, especially 
by hampering the activation of Th1 cells while favoring the differentiation of Treg 
cells [50].
In recent years, a Mexican laboratory led by Salinas [55, 59–61] has focused on the 
study of the immunomodulatory activity of GMP in experimental allergy models. 
They found that oral administration of GMP to rats before and during sensitization 
with allergen significantly reduces the level of allergen-specific IgE in serum, and 
also decreases the proliferative response and the production of IL-13 by splenocytes 
stimulated by the allergen [55]. Treatment of animals with GMP also protected them 
from systemic anaphylaxis as GMP administration increased survival rates and less-
ened signs of severity of anaphylactic shock. Moreover, GMP reduced the intensity 
of urticarial inflammatory reaction when sensitized animals were intradermically 
challenged with the allergen [55]. With these results, it was demonstrated the 
immunomodulatory properties of GMP on allergic sensitization and its beneficial 
effect on clinical signs associated to early-phase allergic reaction. Then, they inves-
tigated whether GMP may impact on late-phase and chronic inflammatory allergic 
reactions, using two experimental models that after repetitive exposure to allergens 
displayed local recruitment and activation of immune cells with persistent produc-
tion of inflammatory mediators in affected tissues, together with substantial changes 
in the extracellular matrix and alterations in structural cells [62]. Specifically, they 
used experimental models of asthma and atopic dermatitis prophylactically admin-
istered with GMP, that is to say, prior to and during pathology establishment. As 
expected, GMP intake resulted in reduction of IgE titers in serum. In addition to this, 
in asthma model, GMP substantially decreased blood eosinophilia and suppressed 
the recruitment of inflammatory cells to the bronchoalveolar compartment. GMP 
also inhibited eosinophils infiltration, goblet cells hyperplasia, and collagen deposit 
in lung tissue [59]. Equivalent results were obtained in allergen-induced atopic 
dermatitis model, where GMP reduced the intensity of cutaneous inflammatory 
process and edema, abolished pruritus, and reduced eosinophils recruitment and 
mast cells hyperplasia in dermis [60]. In both models, expression of IL-5 and IL-13 
was markedly inhibited in lung and skin, while expression of IL-10 was increased. 
Their research then turned to the mechanism by which GMP modulates the allergic 
response. They demonstrated that GMP administration increases the amount of 
Lactobacillus and Bifidobacterium present in gut of allergen-sensitized animals 
after 3 days of oral treatment, and that of Bacteroides after 17 days. Interestingly, 
this intestinal microbiota is associated with protection in allergy. GMP intake also 
increased the production of TGF-β by splenocytes of sensitized animals in response 
to allergen and impacted mast cell function, inhibiting their activation and also the 
release of histamine in response to allergens. No change in tissue mast cell number 
was found [61]. These results obtained in experimental allergy models again show a 
double way by means GMP exerts its control on inflammation; on one hand, through 
a direct modulation of immune cells activity involved in the process, and on other 
side by potentiating a regulatory microenvironment against the Th2-inflammatory 
one. More studies are needed to understand which immune cell receptors recognize 
GMP and which intracellular signals activate or inhibit.
Finally, there are few studies that analyze the role of GMP on cancer. In a rat model 
of pharmacological-induced colorectal cancer, oral administration of 100 mg/kg of 
GMP decreased the number of aberrant crypt foci although no effect was observed at 
doses of 10 and 50 mg/kg. On the other hand, there was no change in methylation and 
expression level of p16 and MUC2, two tumor suppressor genes [63]. Additionally, 
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through an in vitro assay GMP was showed to inhibit the expression of p65 NF-kB in 
human colorectal tumor HT-29 cells activated with LPS, key element in colorectal 
cancer induced by inflammatory bowel diseases [64].
Although more studies are needed in relation to some biological activities, cur-
rent results propose GMP as a good candidate to be used as a functional ingredient 
in food industry.
4. Potential uses of GMP
Today, one of the objectives of the food industry is the development of novel 
food products with beneficial properties for health. For its different health benefits, 
GMP can be used in therapeutic and dietary foods, or as a functional ingredient in 
various special products, like oral care products.
4.1 Therapeutic and nutritional applications
It is crucial to demonstrate that GMP is hypoallergenic to be used in food compo-
sitions. In this regard, Takahashi and collaborators patented a food composition 
that contained GMP and a mixture of free amino acids (leucine, lysine, methionine, 
cysteine, phenylalanine, tyrosine, tryptophan, arginine, histidine, and glycine) 
[65]. The composition presented good taste, good absorption and digestion proper-
ties, and a high nutritional value. They demonstrated that this composition was 
hypoallergenic, as after repeated injections of the GMP composition together with 
an adjuvant used to induce experimental allergy in mice, no antibody against GMP 
was detected in serum by Ouchterlony. Although this method is not very accurate, 
GMP hypoallergenicity was later corroborated by Milkkelsen and collaborators 
using ELISA test to show absence of specific antibodies in mice after being sensi-
tized both systemically or orally with GMP [66].
Due to the particular amino acid composition of GMP, devoid of aromatics 
amino acids (phenylalanine, tryptophan, and tyrosine), it can be used for special 
diets of people suffering from phenylketonuria (PKU), being an adequate choice as 
a source of proteins [67]. On the other hand, GMP has low amount of methionine 
but high amount of branched chain amino acids (valine and isoleucine), which 
makes this peptide an excellent candidate to be used for the control of liver diseases, 
as this type of amino acids are good as caloric sources [68]. There is a patent to use 
of GMP to improve female’s health [69]. The inventors claim that administration of 
a composition comprising GMP can improve the health of the females. They used 
murine models fed with GMP composition and showed that females decreased 
final fat mass and percent body fat, when comparing with females that received a 
diet based on caseins or free amino acids as source of proteins. In relation to bone 
characteristics, femur length was larger in GMP administered mice, although 
only females showed less femoral weakness and greater bone mineral content and 
density as compared to those fed with amino acids or casein diets, respectively.
4.2 Dietary supplementation
As previously mentioned, research results suggest that GMP has an effect on the 
feeling of fullness but this does not translate into a lower food intake [27, 28]. For an 
application in food intake regulation and in potentially body weight management, 
more work is required. Understanding dose, timing, and delivery mode, including 
food form and composition, in relation to the pattern of release of CCK, is needed 
for the use of GMP as appetite suppressant [70].
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4.3 Food additive
GMP has physicochemical properties that make it attractive for use as an addi-
tive in food products. According to studies on the functional properties of GMP, it 
can act as an emulsifier, foaming, and gelling agent.
GMP as an emulsifier presents stability to pH variations, which is attractive 
for foods that undergo pH changes during their process, such as the case of fer-
mented milk products [71]. The best emulsifying capacity was obtained at alkaline 
pH. However, it has been observed that emulsions with GMP as emulsifying agent 
are not stable during storage when they have received thermal treatment [72]. 
Besides, GMP modified covalently with disaccharides or fatty acids can present an 
improved function and even increase its biological activity [73, 74]. Therefore, in 
order to modify the emulsification activity of GMP, this peptide has been conju-
gated with other molecules such as lactose [73] and fatty acids [74]. The conjugation 
of GMP with lactose was carried out through the reaction of Maillard, and this 
conjugate showed a better emulsifying capacity without significantly reducing the 
solubility of GMP [73].
Currently, foams have many industrial uses of great importance in the production 
of beer, soaps, whipped cream, shaving cream, aerosols, etc. The formation of a foam 
requires the participation of a surfactant capable of diffusing to the air/water interface 
to lower the surface tension. GMP complies with this property, although the foams 
formed with GMP are stronger or more stable when combined with other foaming 
proteins [75, 76]. In order to improve the foam properties of the proteins, synergistic 
mixtures of biopolymers and pH variations have been made that can modify their 
charge and, consequently, their foam ability. In relation to this, by combining sodium 
caseinate with GMP, synergistic interactions take place between these molecules on 
foaming and on stability at pH 5.5 [77]. Non-glycosylated GMP has better foaming 
properties than glycosylated GMP [78]. This is due to the glycosidic structures favor 
a combination of hydrophilic and electrostatic effects, which prevents an orderly 
adsorption of the glycosylated GMP molecules at the air/water interface; whereas, 
non-glycosylated GMP forms a very stable network at the interface.
On the other hand, gels are semi-solid systems that consist of a network of 
solids (three-dimensional network of polymers) with an inside trapped-liquid. 
They are of great importance in food and pharmaceutical industry as many gelled 
products are manufactured throughout the world (gummies, gelatins, jelly jams, 
bakery fillings, and therapeutic or cleaning agents). Generally, gelling agents 
are proteins and polysaccharides. Gelling properties of GMP has been studied 
and it is known that its gelation depends on pH and temperature, reporting that 
even aqueous solutions with low GMP amounts can be gelled at pH below 4 [79]. 
Besides, GMP can potentiate gellying capacity of other substances. Thus, by 
fermenting goat milk to which GMP was added, a more ordered and structured gel 
was obtained, in addition to obtaining a better elasticity in it, as compared to that 
obtained when whey protein concentrate was added [80]. The influence of GMP 
on the gelation made by gelatin has also been studied and when these two com-
pounds are mixed, lower concentration of both substances are need to get a gel as 
compared with the ones need when they are used separately [81]. This  synergistic 
effect in gelation is very important in the food industry for the preparation of 
desserts and foods based on gels.
4.4 Oral care products
Dental caries is one of the chronic diseases that most often affect humans. Due 
to the anticariogenic and remineralization properties demonstrated to GMP and 
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previously reviewed in biological activities section, nowadays GMP is being incor-
porated to some oral care products [15–17].
5. GMP as an indicator of milk adulteration with cheese whey
One of the problems presented by the dairy industry is the adulteration of milk 
with whey cheese, which is very cheap and not detected by sensorial tests. Cheese 
whey does not cause harm to health, however, it affects milk-derived products manu-
facturers financially and can affect the consumers nutritionally, so the addition of 
cheese whey is considered a fraud. Due to GMP present in cheese whey, the detection 
of this peptide may indicate the addition of cheese whey to milk. Some of the methods 
that detect GMP as an indicator of the presence of cheese whey are described below.
5.1 Electrophoretic methods
Sodium dodecyl sulfate−polyacrylamide gel (SDS-PAGE): This method was 
standardized to analyze pasteurized milk and milk powder. Samples has to be previ-
ously treated with 24% trichloroacetic acid (TCA) to eliminate interfering k-casein 
and later with 50% TCA to precipitate GMP, which is resuspended in Tris-buffer 
0.05 M HCl, 1 mM EDTA, pH 7.2 [82]. Analyzing under these conditions cheese 
whey and milk added with cheese whey, a protein fraction of 20.8 kDa is identified 
corresponding to GMP that allowed to detect adulteration with whey up to 1%. 
This protein fraction is not detected in samples of acid whey or in raw milk. This 
technique had been previously used to analyze milk drinks that were distributed in 
schools as part of a program of the Brazilian government [83]. However, the method 
showed sensitivity to detect 5% of added whey, probably because they did not treat 
the sample with TCA. In later works, it was able to detect 40 and 20 μg of GMP in 
samples analyzed by electrophoresis in SDS-PAGE and in cellulose acetate strips, 
respectively, due to the use of thiobarbituric acid and malachite green dye reactions 
instead of Coomassie blue as developing agents [84].
Capillary electrophoresis (CE): A variant of electrophoresis is CE, a technique that 
has the advantage of allowing a rapid detection of GMP. This method has been used 
to identify GMP as an indicator of the presence of cheese whey in buttermilk powder 
and skim milk. An advantage of this method is that it is usually reproducible, repeat-
able and sensitive; however, the interpretation of the results is difficult [85].
5.2 Chromatographic method
High performance liquid chromatography (HPLC) has been widely used to iden-
tify GMP as indicative of milk adulteration with cheese whey. In order to carry out 
the analysis, it is necessary to pre-treat the samples with TCA to precipitate proteins 
that can interfere (k-casein) and to concentrate GMP [86]. Similarly, a rapid and 
sensitive HPLC method on a gel permeation column was developed to detect GMP 
to follow the hydrolysis of k-casein by chymosin in milk [87]. The only pretreat-
ment given to samples was addition of TCA (final concentration 8%) to precipitate 
the interfering caseins and whey proteins. This method was widely used by several 
researchers to analyze different samples, such as skimmed milk powder [88]. 
Cation-exchange chromatography has also been used to detect GMP, previously 
removing caseins from whey samples by precipitation with HCl at pH 4.6, neutral-
izing with TCA at 2–8% and analyzing supernatants [89]. On the other hand, a 
Reversed-Phase HPLC (RP-HPLC) method was developed and validated to separate 
and quantify GMP and was demonstrated to be precise, sensitive, and reliable [90]. 
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The determinations were performed in the linear range of 15–200 μg/mL  
and the detection limit was 2 μg/mL. The method was applied to the analysis of 
rennet and acid whey, whey protein concentrates produced by the dairy industry, 
and also for the detection of rennet whey in powdered milks.
The European Commission uses two methods to detect the presence of cheese 
whey in milk: a gel permeation chromatography and subsequently a RP-HPLC as 
a confirmatory test [91]. However, it has been shown that the sensitivity of this 
method is affected by the presence of acidified rennet whey, which makes it dif-
ficult to detect the addition of whey [92]. Besides, the HPLC methodology used to 
analyze compounds like GMP in dairy products usually includes extractions with 
solvents, sample’s preparation require a lot of time and reactives, the equipment is 
very sophisticated and demands trained personal.
5.3 Spectroscopy methods
Spectroscopy has also been used to detect GMP. The medium infrared spectros-
copy (MIR) was used to analyze milk powder in order to detect GMP as adulteration 
parameter. Although this method is fast, it is not widely used because derived 
spectra are not very easy to interpret, in addition to its high cost [93]. On the other 
hand, by liquid chromatography/electrospray coupled to mass spectrometry, milk 
products were analyzed and it was able to quantify GMP from concentration of 
10 pmol, although the method was not used to detect milk adulteration [94].
5.4 Immunochemical methods
Immunoassays are analytical methods of great application in the food area, 
and have the advantages that they are quick, sensitive, and that the sample to be 
analyzed requires little or no treatment. Several immunochemical methods have 
been developed in order to identify and quantify GMP in milk. Firstly, it is neces-
sary to produce antibodies against GMP and later, these antibodies can be used for 
the development of the different immunochemical methods that detect it. Some of 
these assays are described below:
Enzyme-linked immunosorbent assay (ELISA): It is an immunoassay widely used 
to analyze foods. It has the advantage that is simple, sensitive, and fast, in addition 
to being inexpensive. Two main ELISA assays has been developed to detect GMP in 
milk samples. An inhibition ELISA method was performed to detect bovine rennet 
whey solids in skim milk powders that presented a detection limit of 0.1% (w/w) 
and used enzyme-labeled monoclonal antibodies against bovine k-casein [95]. On 
the other hand, Chávez and co-workers [96] developed a sandwich ELISA using 
polyclonal antibodies against GMP, that showed a limit of detection of 0.047% 
(w/w).
Western blot assay: As ELISA, this technique is an immunoassay designed to detect 
proteins in complex samples and also has great specificity. Using the same polyclonal 
antibodies against GMP previously mentioned, Chávez and co-workers developed a 
western blot system to detect GMP [97]. When analyzing cheese whey, this antibody 
recognized three protein fractions of 20.1, 14, and 45 kDa. The detection limit of the 
test was 0.5% (v/v) to liquid cheese whey and 0.001% (w/w) to whey powder.
Immunochromatographic lateral-flow assay: The development of immunochro-
matographic systems for quality control is a relatively new field of research and has 
been applied to milk. There are commercial immunochromatographic sticks which 
contain monoclonal antibodies specific to GMP labeled with colloidal particles that 
present a limit detection of 4% (v/v) of milk whey. Using these immunosticks, it 
has been possible to identify GMP in different samples of commercial milks [98]. 
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Besides, it has been developed an immunochromatographic lateral-flow test that 
used two specific anti-bovine κ-casein monoclonal antibodies, with a detection 
limit of 15 ng/ml of GMP and 1% (v/v) of cheese whey [99].
In summary, different techniques and methods have been developed and used to 
detect GMP as an index of adulteration of milk with cheese whey. Some of them can 
also be used to quantify GMP in food products. The aim of this area of research is to 
achieve one that bring together being cheap, fast, easy to develop, and to interpret 
the results, with high sensitivity and a limited sample processing. These characteris-
tics will allow people to use them at the time and place of milk reception.
6. Conclusions
GMP possesses several nutritional and health promoting properties. Among 
them, it exerts important modulatory effects on the immune system that are 
beneficial in a number of different inflammatory conditions. GMP immune 
response mechanism of action might be mediated by increasing healthy intestinal 
microbiota, by inhibiting splenocyte proliferation, by promoting both local and 
systemic regulatory environment, and also by directly modulating immune cell 
functions. More research is needed to support these findings, as we cannot exclude a 
possible effect of products derived from GMP digestion on in vivo immunomodula-
tory activity. Besides, GMP is a peptide of promising industrial potential. It has a 
unique heat stability and solubility under acidic conditions that may suggest several 
uses in food. Studies on the functional properties of GMP may indicate new possible 
uses as a food additive. On the other hand, several methods have been developed 
and applied to detect GMP as an indicator of milk adulteration with cheese whey; 
however, none of them has been established as an international official method. 
Rapid, reliable, and inexpensive tests to detect GMP should be worked out to readily 
detect those cases of adulteration.
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